Amgen's Patent Tussle Sparks Concerns About Monopolies

A court battle between a large health insurer and Amgen, a big biotech company, has brought attention to the issue of acquiring patent applications and maintaining monopolies on medicines.

The litigation is being closely watched because its outcome could place pharmaceutical patent deals under wider scrutiny. The U.S. Federal Trade Commission (FTC) has unexpectedly weighed in on the side of payers and consumers, arguing that the maneuver deserves attention due to antitrust concerns.

Acquiring a patent application can be seen as a bid to prolong a monopoly, but experts say it's a nuanced issue. The FTC's involvement adds complexity to the case, which is being closely watched by industry observers.